Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor

J. F. Sissom, M. L. Eigenbrodt, J. C. Porter

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Monoclonal antibody (PrR-7A) against purified PRL receptor was used in the following studies. When PRL receptor was chromatographed on affinity columns containing PrR-7A antibody or monoclonal antibody against hemocyanin, which served as a control, PRL receptor was bound to the column containing PrR-7A antibody, but not to the column containing control antibody. When solubilized PRL receptor was incubated with PrR-7A antibody, the specific binding of the receptor was reduced 52%. Female mice were treated with the carcinogen, 7,12-dimethylbenz[α]anthracene, and during the succeeding 48 weeks were treated weekly with PrR-7A antibody or control antibody. In the control group 13% developed mammary carcinomas, and 16% developed moderate-to-severe intraductal hyperplasia. No mammary carcinomas were found in the mice treated with PrR-7A antibody, and only 8% of the mice had moderate-to-severe intraductal hyperplasia. Male mice made hyperprolactinemic by implanted pituitary glands were treated weekly with PrR-7A or control antibody. After 7 weeks of treatment, the mean weight of the prostates of mice treated with PrR-7A antibody was 8 ± 1.1 mg (mean ± SE), and that of mice treated with control antibody was 27 ± 3.6 mg. Similar differences were seen in the protein and DNA content of the prostates. These results indicate that PrR-7A antibody is directed against PRL receptor and that immunization with this antibody reduces the incidence of PRL-dependent mammary tumors and preneoplastic ductal hyperplasia and prevents PRL-induced hyperplasia of the prostate.

Original languageEnglish (US)
Pages (from-to)589-595
Number of pages7
JournalAmerican Journal of Pathology
Volume133
Issue number3
StatePublished - 1988

Fingerprint

Prolactin Receptors
Human Mammary Glands
Prostate
Monoclonal Antibodies
Antibodies
Growth
Hyperplasia
Breast Neoplasms
Hemocyanin
Pituitary Gland
Carcinogens
Immunization

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor. / Sissom, J. F.; Eigenbrodt, M. L.; Porter, J. C.

In: American Journal of Pathology, Vol. 133, No. 3, 1988, p. 589-595.

Research output: Contribution to journalArticle

Sissom, J. F. ; Eigenbrodt, M. L. ; Porter, J. C. / Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor. In: American Journal of Pathology. 1988 ; Vol. 133, No. 3. pp. 589-595.
@article{6edafd282da3440bb8bc488ac98ee7da,
title = "Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor",
abstract = "Monoclonal antibody (PrR-7A) against purified PRL receptor was used in the following studies. When PRL receptor was chromatographed on affinity columns containing PrR-7A antibody or monoclonal antibody against hemocyanin, which served as a control, PRL receptor was bound to the column containing PrR-7A antibody, but not to the column containing control antibody. When solubilized PRL receptor was incubated with PrR-7A antibody, the specific binding of the receptor was reduced 52{\%}. Female mice were treated with the carcinogen, 7,12-dimethylbenz[α]anthracene, and during the succeeding 48 weeks were treated weekly with PrR-7A antibody or control antibody. In the control group 13{\%} developed mammary carcinomas, and 16{\%} developed moderate-to-severe intraductal hyperplasia. No mammary carcinomas were found in the mice treated with PrR-7A antibody, and only 8{\%} of the mice had moderate-to-severe intraductal hyperplasia. Male mice made hyperprolactinemic by implanted pituitary glands were treated weekly with PrR-7A or control antibody. After 7 weeks of treatment, the mean weight of the prostates of mice treated with PrR-7A antibody was 8 ± 1.1 mg (mean ± SE), and that of mice treated with control antibody was 27 ± 3.6 mg. Similar differences were seen in the protein and DNA content of the prostates. These results indicate that PrR-7A antibody is directed against PRL receptor and that immunization with this antibody reduces the incidence of PRL-dependent mammary tumors and preneoplastic ductal hyperplasia and prevents PRL-induced hyperplasia of the prostate.",
author = "Sissom, {J. F.} and Eigenbrodt, {M. L.} and Porter, {J. C.}",
year = "1988",
language = "English (US)",
volume = "133",
pages = "589--595",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor

AU - Sissom, J. F.

AU - Eigenbrodt, M. L.

AU - Porter, J. C.

PY - 1988

Y1 - 1988

N2 - Monoclonal antibody (PrR-7A) against purified PRL receptor was used in the following studies. When PRL receptor was chromatographed on affinity columns containing PrR-7A antibody or monoclonal antibody against hemocyanin, which served as a control, PRL receptor was bound to the column containing PrR-7A antibody, but not to the column containing control antibody. When solubilized PRL receptor was incubated with PrR-7A antibody, the specific binding of the receptor was reduced 52%. Female mice were treated with the carcinogen, 7,12-dimethylbenz[α]anthracene, and during the succeeding 48 weeks were treated weekly with PrR-7A antibody or control antibody. In the control group 13% developed mammary carcinomas, and 16% developed moderate-to-severe intraductal hyperplasia. No mammary carcinomas were found in the mice treated with PrR-7A antibody, and only 8% of the mice had moderate-to-severe intraductal hyperplasia. Male mice made hyperprolactinemic by implanted pituitary glands were treated weekly with PrR-7A or control antibody. After 7 weeks of treatment, the mean weight of the prostates of mice treated with PrR-7A antibody was 8 ± 1.1 mg (mean ± SE), and that of mice treated with control antibody was 27 ± 3.6 mg. Similar differences were seen in the protein and DNA content of the prostates. These results indicate that PrR-7A antibody is directed against PRL receptor and that immunization with this antibody reduces the incidence of PRL-dependent mammary tumors and preneoplastic ductal hyperplasia and prevents PRL-induced hyperplasia of the prostate.

AB - Monoclonal antibody (PrR-7A) against purified PRL receptor was used in the following studies. When PRL receptor was chromatographed on affinity columns containing PrR-7A antibody or monoclonal antibody against hemocyanin, which served as a control, PRL receptor was bound to the column containing PrR-7A antibody, but not to the column containing control antibody. When solubilized PRL receptor was incubated with PrR-7A antibody, the specific binding of the receptor was reduced 52%. Female mice were treated with the carcinogen, 7,12-dimethylbenz[α]anthracene, and during the succeeding 48 weeks were treated weekly with PrR-7A antibody or control antibody. In the control group 13% developed mammary carcinomas, and 16% developed moderate-to-severe intraductal hyperplasia. No mammary carcinomas were found in the mice treated with PrR-7A antibody, and only 8% of the mice had moderate-to-severe intraductal hyperplasia. Male mice made hyperprolactinemic by implanted pituitary glands were treated weekly with PrR-7A or control antibody. After 7 weeks of treatment, the mean weight of the prostates of mice treated with PrR-7A antibody was 8 ± 1.1 mg (mean ± SE), and that of mice treated with control antibody was 27 ± 3.6 mg. Similar differences were seen in the protein and DNA content of the prostates. These results indicate that PrR-7A antibody is directed against PRL receptor and that immunization with this antibody reduces the incidence of PRL-dependent mammary tumors and preneoplastic ductal hyperplasia and prevents PRL-induced hyperplasia of the prostate.

UR - http://www.scopus.com/inward/record.url?scp=0024204950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024204950&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 589

EP - 595

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -